CD30/TNFRSF8 Antibody [Biotin] Summary
Immunogen |
S. frugiperda insect ovarian cell line Sf 21-derived recombinant human CD30/TNFRSF8 Phe19-Lys379 Accession # P28908 |
Specificity |
Detects human CD30/TNFRSF8 in Western blots. In Western blots, less then 1% cross-reactivity with recombinant mouse CD30 is observed. |
Source |
N/A |
Isotype |
IgG |
Clonality |
Polyclonal |
Host |
Goat |
Gene |
TNFRSF8 |
Purity Statement |
Antigen Affinity-purified |
Innovator's Reward |
Test in a species/application not listed above to receive a full credit towards a future purchase. |
Packaging, Storage & Formulations
Storage |
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. - 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 6 months, -20 to -70 °C under sterile conditions after reconstitution.
|
Buffer |
Lyophilized from a 0.2 μm filtered solution in PBS with BSA as a carrier protein. |
Preservative |
No Preservative |
Concentration |
LYOPH |
Reconstitution Instructions |
Reconstitute at 0.2 mg/mL in sterile PBS. |
Notes
This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.
Background
CD30, also known as Ki-1 antigen and TNFRSF8, is a 120 kDa type I transmembrane glycoprotein belonging to the TNF receptor superfamily (1, 2). Mature human CD30 consists of a 361 amino acid (aa) extracellular domain (ECD) with six cysteine-rich repeats, a 28 aa transmembrane segment, and a 188 aa cytoplasmic domain (3). In contrast, mouse and rat CD30 lack 90 aa of the ECD and contain only three cysteine-rich repeats. Within common regions of the ECD, human CD30 shares 53% and 49% aa sequence identity with mouse and rat CD30, respectively. Alternate splicing of human CD30 generates an isoform that includes only the C‑terminal 132 aa of the cytoplasmic domain. CD30 is normally expressed on antigen-stimulated Th cells and B cells (4‑6). However, it is upregulated in Hodgkin’s disease (on Reed-Sternberg cells), other lymphomas, chronic inflammation, and autoimmunity (7). CD30 binds to CD30 Ligand/TNFSF8 which is expressed on activated Th cells, monocytes, granulocytes and medullary thymic epithelial cells (1, 5). CD30 signaling costimulates antigen-induced Th0 and Th2 proliferation and cytokine secretion but favors a Th2-biased immune response (8). In the absence of antigenic stimulation, it can still induce T cell expression of IL-13 (9). CD30 contributes to thymic negative selection by inducing the apoptotic cell death of CD4+CD8+ T cells (10, 11). In B cells, CD30 ligation promotes cellular proliferation and antibody production in addition to the expression of CXCR4, CCL3, and CCL5 (5, 12). An 85-90 kDa soluble form of CD30 is shed from the cell surface by TACE-mediated cleavage (13, 14). Soluble CD30 retains the ability to bind CD30 Ligand and functions as an inhibitor of normal CD30 signaling (15).
- Kennedy, M.K. et al. (2006) Immunology 118:143.
- Tarkowski, M. (2003) Curr. Opin. Hematol. 10:267.
- Durkop, H. et al. (1992) Cell 68:421.
- Hamann, D. et al. (1996) J. Immunol. 156:1387.
- Shanebeck, S.D. et al. (1995) Eur. J. Immunol. 25:2147.
- Gruss, H.-J. et al. (1994) Blood 83:2045.
- Oflzoglu E. et al. (2009) Adv. Exp. Med. Biol. 647:174.
- Del Prete, G. et al. (1995) J. Exp. Med. 182:1655.
- Harlin, H. et al. (2002) J. Immunol. 169:2451.
- Amakawa, R. et al. (1996) Cell 84:551.
- Chiarle, R. et al. (1999) J. Immunol. 163:194.
- Vinante, F. et al. (2002) Blood 99:52.
- Hansen, H.P. et al. (1995) Int. J. Cancer 63:750.
- Hansen, H.P. et al. (2000) J. Immunol. 165:6703.
- Hargreaves, P.G. and A. Al-Shamkhani (2002) Eur. J. Immunol. 32:163.
Limitations
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are
guaranteed for 1 year from date of receipt.
Customers Who Viewed This Item Also Viewed...
Species: Hu
Applications: BA
Species: Hu, Mu
Applications: Flow-IC, Flow, ICC/IF, IHC, IHC-Fr, IHC-P, IP, WB
Species: Hu
Applications: CyTOF-ready, ELISA, Flow, ICC/IF, IHC, IHC-P, PA, WB
Species: Ca, Hu, Mu, Po
Applications: Flow, ICC/IF, IHC, IHC-Fr, IHC-P, KD
Species: Hu, Rt
Applications: Flow, ICC/IF, IHC, IHC-P, IP, WB
Species: Hu
Applications: BA
Species: Hu, Mu
Applications: Flow, WB
Species: Mu
Applications: CyTOF-ready, Flow, ICC, IHC, WB
Species: Ca, Hu, Mu, Po, Rb, Rt
Applications: Dual ISH-IHC, Flow, ICC/IF, IHC, IHC-Fr, IHC-P, Simple Western, WB
Species: Hu
Applications: BA
Species: Hu
Applications: BA
Species: Hu
Applications: CyTOF-ready, Flow, IHC, WB
Species: Mu, Rt
Applications: Cell Depl, CyTOF-ready, Flow, ICC/IF, IHC, IHC-Fr, IHC-P, IP, InhibTFunc
Species: Hu
Applications: ELISA
Species: Hu, Mu
Applications: ELISA, Flow, ICC/IF, IHC, IHC-Fr, IHC-P
Species: Hu
Applications: ELISA, ICC/IF, S-ELISA, WB
Species: Hu
Applications: IHC, Simple Western, WB
Species: Hu
Applications: BA
Publications for CD30/TNFRSF8 Antibody (BAF229) (0)
There are no publications for CD30/TNFRSF8 Antibody (BAF229).
By submitting your publication information earn gift cards and discounts for future purchases.
Reviews for CD30/TNFRSF8 Antibody (BAF229) (0)
There are no reviews for CD30/TNFRSF8 Antibody (BAF229).
By submitting a review you will receive an Amazon e-Gift Card or Novus Product Discount.
- Review with no image -- $10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen
- Review with an image -- $25/€18/£15/$25 CAD/¥150 Yuan/¥2500 Yen
FAQs for CD30/TNFRSF8 Antibody (BAF229) (0)